


Cell Reports, Volume 37

Supplemental information

**A potent bispecific nanobody
protects hACE2 mice against SARS-CoV-2
infection via intranasal administration**

Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, and Zhiwei Wu

- 1 **This file includes:**
 2 Supplemental Figures 1 to 7
 3 Supplemental Table 1 to 3
 4




- 5
 6 **Supplemental Figure 1. Characterization of anti-sera specific for SARS-CoV-2. Related to Figure**
 7 **1. (A)** The experimental schedule for immunization. The titer of anti-sera specific for SARS-CoV-2 S
 8 protein **(B)** and RBD protein **(C)** was evaluated one week after the immunization in alpaca receiving
 9 SARS-CoV-2 spike protein, respectively. The titer of the third anti-serum was indicated as blue line.
 10 The blue # indicates the anti-serum titer after the third immunization. 3rd anti-serum and 2nd anti-serum
 11 represent the anti-sera collected from alpaca one week after the 3rd and 2nd immunization. Blank serum
 12 represents the alpaca serum collected before immunization, which was taken as a negative control. **(D)**
 13 Neutralization potency of the immunized alpaca's serum against pseudotyped SARS-CoV-2 was
 14 detected. ND₅₀: half-maximal serum neutralization dilution titer. Titer and ND₅₀ were indicated. Data of
 15 B-D represent as mean ± SEM. All experiments of B-D were repeated twice.
 16
 17

A

The summary of C9-Nb library

Name	Library size	Sequencing clone	Sequence results	In frame clone	Diversity	In frame rate
C9-Nb-lib	2.0×10^9	25	25	24	24/24 100%	24/25 96%




18

19 **Supplemental Figure 2. The construction and biopanning of C9-Nb library. Related to Figure 1.**

20 (A) The table summary of C9-Nb library, wherein phage displayed Nb of PBMC from alpaca receiving
21 three times immunization of SARS-CoV-2 S protein. (B) The binding of the phage library with S via
22 phage ELISA. Lib is the phage library of C9-Nb; 1st, 2nd, and 3rd are the phage library after panning on
23 1 round, 2 rounds, and 3 rounds of S protein enrichment, respectively. (C) Single clone of phages from
24 the C9-Nb library after the second and third enrichment of SARS-CoV-2 S were analyzed by phage
25 ELISA. One dot represents the supernatant binding of one clone. Positive rate was indicated.

26

27



28

29 **Supplemental Figure 3. Characterization of Nb-Fc. Related to Figure 1.** (A) The diagram of Nb-Fc,

30 constituted by Nb fusing with human Fc1. (B) 21 various Nb-Fcs binding with S and RBD protein

31 identified by ELISA. Grey dot represents negative control. Green dots represent the specific binding

32 with S protein. Blue dots represent the double binding with S and RBD protein. (C) Representative

33 binding curve of Nb-Fcs with RBD tested by BLI. (D) The table summary of 21 Nb-Fcs binding with


34 RBD tested by BLI. (E) The cell supernatants of 21 various Nb-Fcs were tested for neutralization

35 against SARS-CoV-2 infection, the cell supernatant displaying outstanding neutralizing curve was

36 labeled as the color-coded curve. Data of B represent as mean \pm SEM. All experiments of B-E were

37 repeated twice

38




39

40 **Supplemental Figure 4. Characterization of purified Nb-Fcs. Related to Figure 1.** (A) Purified Nb-
 41 Fcs binding with RBD identified by ELISA. Data represent as mean \pm SEM. (B) RBD protein under
 42 reducing condition (R) or non-reducing condition (NR) was detected by WB with Nb₁₅-Fc, Nb₂₂-Fc and
 43 Nb₃₁-Fc. Kinetic binding curve of RBD with Nb₁₅-Fc (C), Nb₂₂-Fc (D) and Nb₃₁-Fc (E), respectively.
 44 Binding curves are colored black, and fit of the data to a 1:1 binding model is colored red.

45

46

Fig. S5



47

48 **Supplemental Figure 5. Epitope analysis of Nb-Fcs by BLI. Related to Figure 1.** RBD protein was

49 coated on the sensor, Nb₁₅-Fc (A), Nb₂₂-Fc (B) or Nb₃₁-Fc(C) as the first antibody was added to bind

50 for 300 s following with the baseline step with 30 s immersion in 0.02% PBST. The second competing


51 concentration of Nb (50 µg/ml) was then added for 300 sec to measure binding in the presence of the

52 first saturating Nb.

53

54

55




E Summary of C9Nbs inhibiting SARS-CoV-2 live virus

$\mu\text{g/ml}$	SARS-CoV-2 live virus		
	IC ₅₀	IC ₈₀	IC ₉₀
Nb ₁₅ -Fc	0.0033	0.0084	0.0156
Nb ₂₂ -Fc	0.0068	0.0108	0.0159
Nb ₃₁ -Fc	0.0036	0.0100	0.0235

56

57 **Supplemental Figure S6. Characterizing the potency of neutralization against authentic**
 58 **SARS-CoV-2 conferred by Nb-Fcs. Related to Figure 1.** The neutralization potency of Nb₁₅-Fc
 59 (A), Nb₂₂-Fc (B), Nb₃₁-Fc(C), SNB02 (isotype control antibody) (D) was detected based on
 60 authentic SARS-CoV-2 plaque reduction neutralization test. The raw data was depicted. (E) A table
 61 summary authentic SARS-CoV-2 neutralization potencies of Nb-Fcs.



62

63 **Supplemental Figure 7. Kinetic binding curve of Nb₁₅-Nb_H-Nb₁₅ with MSA. Related to Figure 5.**

64 Kinetic binding curve of Nb₁₅-Nb_H-Nb₁₅ at the concentration of 300 nM, 100nM, 33.3 nM, 11.1nM,

65 3.7nM and 1.2 nM with MSA by BLI. Binding curves are colored black, and fit of the data to a 1:1

66 binding model is colored red.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

Supplemental Table 1. Summary of CDR sequences of positive Nb clones. Related to Figure 1.

ID	CDR1	CDR2	CDR3
Nb₁-Fc	GNIFSIYT	VTSGGST	N-----ARLFDPGY
Nb₂-Fc	GGTLASFA	INIINRT	AAHFVPPGSRLRDCLVNELYNY
Nb₄-Fc	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNELYNY
Nb₅-Fc	GFTWNYHA	ISSSGSTT	AAPHSGSVCPR--WAEYYGVDH
Nb₇-Fc	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNEAYNY
Nb₉-Fc	GGTLASFA	INIINRT	AAHFVPPGGRLRGCLVNDLYNY
Nb₁₂-Fc	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNDLYNY
Nb₁₃-Fc	GGTLASFA	ITNSGST	N-----TFHY
Nb₁₄-Fc	GGTLASFA	ISSSGGST	TARPSLWAVVAGCPLDQNTYFS
Nb₁₅-Fc	GGTLASFA	ISSSGST	AG-VVHDVQAM--CVMNP-WGS
Nb₁₉-Fc	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNDVYNY
Nb₂₂-Fc	GGTLASFA	IDVINRA	AAHFVPPGSRLRGCLVNELYNY
Nb₂₄-Fc	GGTLASFA	INIINRT	AAHFVPPESRLRGCLVNELYNY
Nb₂₅-Fc	GGTLASFA	ITSRRDT	YG-----QDVLGQIY
Nb₂₇-Fc	GGTLASFA	ITSGGST	TT-----AGSWQGDY
Nb₂₈-Fc	GGTLASFA	INIINRT	AAHFVPPESRLRGCLVNEAYNY
Nb₂₉-Fc	GGTLASFA	ISSRSFT	YG-----QDILGQIY
Nb₃₀-Fc	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNELYNY
Nb₃₁-Fc	GGTLASFA	INIINRP	AAHFVPPGSRLGGCLVNELYNY
Nb₃₃-Fc	GGTLASFA	INIINRT	AAHFVPPGSRFRGCSVNELYNY
Nb₃₄-Fc	GGTLASFA	INIINRP	AAHFVPPGSRLGGCLVNELYNY
Nb_H	GFILDYYA	IDSSGGTT	AAGGDLGVGQCSTWVRAYDY

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112
113
114

Supplemental Table 2. Summary of Nbs inhibiting SARS-CoV-2 variants. Related to Figure 1.

Variants	Nb ₁₅ -Fc (mean±sd µg/ml)			Nb ₂₂ -Fc (mean±sd µg/ml)			Nb ₃₁ -Fc (mean±sd µg/ml)			Nb ₁₅ -Nb _H -Nb ₁₅ (mean±sd µg/ml)		
	IC ₅₀	IC ₈₀	IC ₉₀	IC ₅₀	IC ₈₀	IC ₉₀	IC ₅₀	IC ₈₀	IC ₉₀	IC ₅₀	IC ₈₀	IC ₉₀
WT	0.0008±0.0001	0.0019±0.0004	0.0033±0.0012	0.0016±0.0001	0.0046±0.0012	0.0086±0.0033	0.0023±0.0004	0.0083±0.0019	0.0183±0.0059	0.0004±0	0.0012±0.0004	0.0018±0.0009
Q321L	0.0009±0.0004	0.0023±0.0007	0.0039±0.0008	0.0014±0.0003	0.0042±0.0009	0.0079±0.0019	0.002±0.0005	0.0065±0.0017	0.0133±0.0033	0.001±0.0001	0.0022±0.0004	0.0034±0.0009
V341I	0.0007±0.0002	0.0026±0.0005	0.0059±0.0019	0.0017±0.0005	0.0042±0.0007	0.007±0.001	0.0028±0.0004	0.0087±0.0024	0.0169±0.0058	0.0011±0.0001	0.0027±0.0009	0.0047±0.0022
A348T	0.001±0.0002	0.0023±0.0003	0.0036±0.0005	0.0019±0.0008	0.0046±0.0012	0.0076±0.0016	0.0029±0.0001	0.0088±0.0013	0.0176±0.0032	0.0008±0.0002	0.0014±0.0001	0.0019±0.0004
N354D	0.0008±0.0002	0.0022±0.0002	0.0041±0.001	0.0013±0.0003	0.0033±0.0005	0.0056±0.0012	0.0019±0.0001	0.0068±0.0018	0.0145±0.0051	0.0006±0.0002	0.0016±0.0006	0.0032±0.0013
S359N	0.0011±0.0001	0.0026±0.0003	0.0043±0.0006	0.0016±0.0003	0.0037±0.0005	0.0061±0.0008	0.002±0.0005	0.0064±0.0012	0.0129±0.0037	0.0008±0.0002	0.0017±0.0002	0.0025±0.0005
V367F	0.0007±0.0001	0.002±0.0002	0.0036±0.0004	0.0011±0.0003	0.0033±0.0003	0.0062±0.0004	0.0021±0.0006	0.0095±0.0017	0.0237±0.0022	0.0005±0	0.0013±0.0001	0.0026±0.0006
K378R	0.0007±0.0002	0.0024±0.0003	0.0046±0.0001	0.0012±0.0002	0.0028±0.0003	0.0045±0.0005	0.0013±0.0001	0.004±0.0004	0.0079±0.0017	0.0008±0.0002	0.002±0.0004	0.0033±0.0006
R408I	0.0007±0.0002	0.002±0.0007	0.0035±0.0016	0.001±0.0001	0.0027±0.0003	0.0047±0.0009	0.0014±0.0002	0.0038±0.001	0.0069±0.0026	0.0007±0.0001	0.0014±0.0002	0.002±0.0005
Q409E	0.0005±0.0001	0.0014±0	0.0026±0.0002	0.0009±0.0003	0.0022±0.0007	0.0036±0.0011	0.0009±0.0001	0.0029±0.0004	0.0057±0.0007	0.0007±0.0002	0.0014±0.0002	0.0021±0.0003
K458R	0.0009±0.0003	0.0025±0.0002	0.0047±0.0006	0.0013±0.0001	0.0041±0.0014	0.008±0.0036	0.0025±0.0003	0.0068±0.0013	0.0128±0.004	0.0008±0.0002	0.0018±0.0003	0.0029±0.0004
G476S	0.0006±0.0002	0.0015±0.0004	0.0025±0.0006	0.0013±0.0006	0.0034±0.0011	0.006±0.0013	0.0015±0.0001	0.0049±0.0008	0.0101±0.0023	0.0003±0.0001	0.0009±0.0002	0.0014±0.0003
V483A	0.0006±0.0001	0.0017±0.0005	0.0031±0.0011	0.0015±0.0003	0.0039±0.0008	0.0069±0.0026	0.0027±0.001	0.0093±0.0018	0.0206±0.0027	0.0005±0.0001	0.0013±0	0.0022±0.0002
Y508H	0.0005±0.0001	0.0023±0.0003	0.0053±0.001	0.0013±0.0002	0.0035±0.0007	0.006±0.0015	0.0018±0.0005	0.0068±0.0007	0.0157±0.0047	0.0008±0.0001	0.0019±0.0006	0.0033±0.0016
H519P	0.0008±0.0001	0.0023±0.0002	0.0041±0.0005	0.0011±0.0002	0.0033±0	0.006±0.0004	0.0014±0.0003	0.005±0.0004	0.0107±0.0032	0.0007±0.0002	0.0016±0.0001	0.0025±0.0002
D614G	0.0007±0.0001	0.002±0.0002	0.0035±0.0007	0.0012±0.0005	0.0033±0.0005	0.0059±0.0003	0.0015±0.0004	0.0039±0.001	0.0067±0.0016	0.0006±0.0001	0.0015±0.0005	0.0026±0.001
A435S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0007±0.0001	0.0015±0.0003	0.0024±0.0006
I472V	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0006±0.0001	0.0014±0.0003	0.0023±0.0006
E484K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	>1.000	>1.000	>1.000
N501Y	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0007±0.0002	0.002±0.0005	0.0042±0.0013

Note: N/A, no test

115
116
117
118
119
120
121

122
123
124

Supplemental Table 3. Summary of RBD binding with Nb_{15S} in different conditions. **Related to Figure 5.**

Sample ID	Condition	Conc. (nM)	Response	KD (M)	Ka(1/Ms)	Kd(1/s)	RMax	Full R ²
Nb ₁₅ -Nb _H -Nb ₁₅	WT	133.3	0.3806	<1.0E-12	3.44E+05	<1.0E-07	0.3687	0.9676
	Aero	133.3	0.2139	9.92E-09	4.11E+04	4.08E-04	0.3277	0.9957
	37 °C	133.3	0.3756	<1.0E-12	1.89E+05	<1.0E-07	0.374	0.9948
	50 °C	133.3	0.3903	5.78E-11	2.11E+05	1.22E-05	0.3849	0.996
	60 °C	133.3	0.4048	5.57E-10	1.91E+05	1.06E-04	0.402	0.9986
	70 °C	133.3	0.3775	2.52E-10	1.63E+05	4.10E-05	0.3801	0.9989
	80 °C	133.3	0.3199	5.64E-09	5.85E+04	3.30E-04	0.4193	0.9994
	90 °C	133.3	0.1078	1.02E-08	2.90E+04	2.95E-04	0.211	0.9978
Nb ₁₅ -Fc	WT	62.5	0.8028	<1.0E-12	6.98E+05	<1.0E-07	0.7814	0.9824
	Aero	62.5	0.3398	2.79E-10	5.05E+04	1.41E-05	0.7387	0.999
	37 °C	62.5	0.8136	<1.0E-12	4.34E+05	<1.0E-07	0.804	0.9946
	50 °C	62.5	0.853	<1.0E-12	4.11E+05	<1.0E-07	0.848	0.9976
	60 °C	62.5	0.7989	4.38E-11	4.11E+05	1.80E-05	0.7944	0.9979
	70 °C	62.5	0.6126	4.95E-09	8.87E+04	4.39E-04	0.956	0.9995
	80 °C	62.5	0.2077	1.98E-08	4.16E+04	8.26E-04	0.557	0.9983
	90 °C	62.5	0.1088	4.12E-08	2.76E+04	1.14E-03	0.4281	0.9978
3xNb ₁₅	WT	133.3	0.3769	<1.0E-12	6.20E+05	<1.0E-07	0.3637	0.8833
	Aero	133.3	0.184	<1.0E-12	2.55E+04	<1.0E-07	0.3816	0.9946
	37 °C	133.3	0.3667	<1.0E-12	4.01E+05	<1.0E-07	0.3578	0.9563
	50 °C	133.3	0.3588	<1.0E-12	3.96E+05	<1.0E-07	0.3507	0.9583
	60 °C	133.3	0.3715	<1.0E-12	3.49E+05	<1.0E-07	0.3635	0.9717
	70 °C	133.3	0.2294	<1.0E-12	2.78E+04	<1.0E-07	0.4508	0.9975
	80 °C	133.3	0.2748	4.97E-10	4.53E+04	2.25E-05	0.4052	0.9994
	90 °C	133.3	0.1294	4.87E-09	5.21E+04	2.54E-04	0.1778	0.9968

125
126
127
128
129